PDB38 - BUDGET IMPACT ANALYSIS OF BENAGLUTIDE INJECTION IN THE TREATMENT OF TYPE 2 DIABETES IN CHINA

Abstract

The study aimed to compare the impact on insurance capital of use of Benaglutide injection versus Liraglutide injection in the treatment of type 2 diabetes in China from payers’ perspectives on both national and provincial levels. A Budget impact model was conducted to estimate the effect of variation of market share of Benaglutide injection compared to Liraglutide injection on health insurance in 1-3 year Epidemic information, drug price, dosage use in clinical practice were provided, as well as population characteristics on national and provincial levels in this model. Benaglutide injection and Liraglutide injection account for 3% and 65% of GLP-1 in Chinese market respectively which corresponds to a population of 26,307 and 631,379 nationwide. Given that the dosage use in clinical practice of the two injections are 0.28 mg/d and 1.3 mg/d and the average cost of Benaglutide injection and Liraglutide injection are 100 yuan/mg and 22.8 yuan/mg respectively, we estimated that the average cost of Benaglutide injection and Liraglutide injection is 28.4 CNY/day, 29.1 CNY/day respectively. The total cost of treatment of type 2 diabetes using the two injections for 1 year is 272,775,232 CNY and 6,702,200,040 CNY respectively on the national level. With Benaglutide injection replace Liraglutide injection rate varing between 10%∼100%, the total cost of treatment using the two drugs changed in a spectrum of 6,546,605,572 CNY and 6,686,640,594 CNY, saving a cost of 15,559,447 to 155,594,468 CNY. Sensitivity analysis showed consistency of the result with adjustments to provinces & municipalities level and time horizon in the model. Use of Benaglutide injection in the treatment of type 2 diabetes in China is cost saving for Chinese health insurance budget compared to Liralutide injection. With the market share of Benaglutide injection increasing, the cost was saved more.